PT92174A - Processo para aumentar a hemoglobina fetal mediante tratamento com actividade e/ou inibina - Google Patents

Processo para aumentar a hemoglobina fetal mediante tratamento com actividade e/ou inibina

Info

Publication number: PT92174A
Authority: PT; Portugal
Prior art keywords: inible; activity; treatment; beta; globin
Prior art date: 1988-11-01

Application number

PT92174A

Other languages

English (en)

Other versions

PT92174B (pt

Original Assignee

Susan P Perrine

Norbert Alberts

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-01

Filing date

1989-11-02

Publication date

1990-05-31

1989-11-02 Application filed by Susan P Perrine, Norbert Alberts filed Critical Susan P Perrine

1990-05-31 Publication of PT92174A publication Critical patent/PT92174A/pt

1995-09-12 Publication of PT92174B publication Critical patent/PT92174B/pt

Links

108010044495 Fetal Hemoglobin Proteins 0.000 title 1
230000000694 effects Effects 0.000 title 1
102100021519 Hemoglobin subunit beta Human genes 0.000 abstract 2
108091005904 Hemoglobin subunit beta Proteins 0.000 abstract 2
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 abstract 2
102000005606 Activins Human genes 0.000 abstract 1
108010059616 Activins Proteins 0.000 abstract 1
108091005886 Hemoglobin subunit gamma Proteins 0.000 abstract 1
102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 abstract 1
208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
206010043391 Thalassaemia beta Diseases 0.000 abstract 1
239000000488 activin Substances 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000893 inhibin Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000007056 sickle cell anemia Diseases 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT92174A 1988-11-01 1989-11-02 Processo para aumentar a hemoglobina fetal mediante tratamento com actividade e/ou inibina PT92174B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/266,421 US4997815A (en)	1988-11-01	1988-11-01	Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin

Publications (2)

Publication Number	Publication Date
PT92174A true PT92174A (pt)	1990-05-31
PT92174B PT92174B (pt)	1995-09-12

Family

ID=23014518

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT92174A PT92174B (pt)	1988-11-01	1989-11-02	Processo para aumentar a hemoglobina fetal mediante tratamento com actividade e/ou inibina

Country Status (9)

Country	Link
US (1)	US4997815A (pt)
EP (2)	EP0367590B1 (pt)
JP (1)	JPH02256622A (pt)
AT (1)	ATE119396T1 (pt)
CA (1)	CA2001897A1 (pt)
DE (1)	DE68921546T2 (pt)
IL (1)	IL92167A (pt)
MA (1)	MA21667A1 (pt)
PT (1)	PT92174B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03173805A (ja) *	1989-09-11	1991-07-29	Ajinomoto Co Inc	卵分割促進剤
US5102868A (en) *	1990-01-08	1992-04-07	Genentech, Inc.	Method for inhibiting follicular maturation
US5166190A (en) *	1990-01-08	1992-11-24	Genentech, Inc.	Method for increasing fertility in males
US5942220A (en) *	1990-03-16	1999-08-24	Chiron Corporation	Inhibitor of cytokine activity and applications thereof
WO1991012334A1 (en) *	1990-02-15	1991-08-22	Cetus Corporation	Inhibitor of cytokine activity and applications thereof
EP0548276A4 (en) *	1990-09-13	1993-12-29	Children's Hospital Medical Center Of Northern California	Method for increasing red blood cell production by treatment with activin or activin-related peptides
US7910624B1 (en)	1995-03-03	2011-03-22	The Trustees Of Boston University	Compositions for the treatment of blood disorders
USD354971S (en)	1993-07-26	1995-01-31	Mugnier Design	Eyeglasses
EP0664699A1 (en) *	1993-08-13	1995-08-02	Vitaphore Corporation	Hydrogel-based microsphere drug delivery systems
US5487895A (en) *	1993-08-13	1996-01-30	Vitaphore Corporation	Method for forming controlled release polymeric substrate
RO115498B1 (ro) *	1993-10-29	2000-03-30	Univ Boston	Metoda de tratament a neoplasmului
US5700640A (en) *	1994-09-16	1997-12-23	Basf Aktiengesellschaft	Inducers of gamma globin gene expression and screening assays therefor
US5545616A (en) *	1994-09-22	1996-08-13	Genentech, Inc.	Method for predicting and/or preventing preterm labor
US6011000A (en) *	1995-03-03	2000-01-04	Perrine; Susan P.	Compositions for the treatment of blood disorders
GB2306481A (en) *	1995-10-21	1997-05-07	Univ Manchester	Pharmaceutical comprising a stimulator of activin and/or inhibin
EP1886677A1 (en)	1996-07-26	2008-02-13	Susan P. Perrine	Use of an inducing agent for the treatment of blood, viral and cellular disorders
AUPO638897A0 (en) *	1997-04-23	1997-05-22	Monash University	Modulation of cell growth and methods relating thereto
US6822267B1 (en) *	1997-08-20	2004-11-23	Advantest Corporation	Signal transmission circuit, CMOS semiconductor device, and circuit board
CA2324426A1 (en) *	1998-02-11	1999-08-19	Douglas V. Faller	Compositions and methods for the treatment of cystic fibrosis
SG141296A1 (en)	2002-05-17	2008-04-28	Sinai School Medicine	Mesoderm and definitive endoderm cell populations
AU2012203441B2 (en) *	2002-05-17	2015-01-29	Mount Sinai School Of Medicine Of New York University	Mesoderm and definitive endoderm cell populations
US20060003446A1 (en)	2002-05-17	2006-01-05	Gordon Keller	Mesoderm and definitive endoderm cell populations
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
KR20050122210A (ko) *	2003-03-17	2005-12-28	다케다 샌디에고, 인코포레이티드	히스톤 탈아세틸화 효소 억제제
WO2005066151A2 (en) *	2003-12-19	2005-07-21	Takeda San Diego, Inc.	Histone deacetylase inhibitors
WO2005065681A1 (en) *	2003-12-19	2005-07-21	Takeda San Diego, Inc.	N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2006020683A1 (en) *	2004-08-10	2006-02-23	Voyager Pharmaceutical Corporation	Methods for treating premature infants
JP2008524246A (ja) *	2004-12-16	2008-07-10	タケダサンディエゴインコーポレイテッド	ヒストンデアセチラーゼ阻害剤
WO2006122319A2 (en) *	2005-05-11	2006-11-16	Takeda San Diego, Inc.	Histone deacetylase inhibitors
ZA200800901B (en) *	2005-07-14	2010-05-26	Takeda San Diego Inc	Histone deacetylase inhibitors
WO2007084390A2 (en) *	2006-01-13	2007-07-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US8874380B2 (en)	2010-12-09	2014-10-28	Rutgers, The State University Of New Jersey	Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
WO2010105112A1 (en) *	2009-03-11	2010-09-16	Hemaquest Pharmaceuticals, Inc.	Detection of short-chain fatty acids in biological samples
US20110086869A1 (en)	2009-09-24	2011-04-14	The Trustees Of Boston University	Methods for treating viral disorders
US8618068B2 (en)	2009-12-08	2013-12-31	Trustees Of Boston University	Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en)	2010-03-11	2011-10-06	Hemaquest Pharmaceuticals, Inc.	Methods and Compositions for Treating Viral or Virally-Induced Conditions
US10039813B2 (en)	2012-02-07	2018-08-07	Massachusetts Institute Of Technology	Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9724396B2 (en)	2013-03-15	2017-08-08	Massachusetts Institute Of Technology	Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016064815A1 (en) *	2014-10-20	2016-04-28	Massachusetts Institute Of Technology	Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
US10317418B2 (en)	2015-02-24	2019-06-11	Massachusetts Institute Of Technology	Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
JP7373991B2 (ja)	2016-07-15	2023-11-06	ビラクタセラピューティクス，インク．	免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
MX2021014639A (es)	2019-05-31	2022-04-06	Viracta Subsidiary Inc	Metodos para tratar canceres asociados con virus con inhibidores de la histona deacetilasa.
CN118354759A (zh)	2021-10-19	2024-07-16	阿基拉比奥有限公司	包含2’-脱氧胞苷类似物的组合物及其用于治疗镰状细胞病、地中海贫血和癌症的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0730114B2 (ja) *	1985-04-03	1995-04-05	正雄五十嵐	インヒビン
JPH0637520B2 (ja) *	1985-07-03	1994-05-18	味の素株式会社	ポリペプチド
US4740587A (en) *	1985-07-18	1988-04-26	The Salk Institute For Biological Studies	Inhibin and method of purifying same
NZ231899A (en) *	1985-10-03	1991-07-26	Genentech Inc	Human or porcine inhibin peptide compositions and dna encoding them
NZ217821A (en) *	1985-10-10	1989-07-27	Biotech Australia Pty Ltd	Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4822821A (en) *	1986-10-10	1989-04-18	Children's Hospital Medical Center Of Northern California	Method for augmenting fetal hemoglobin
AU610858B2 (en) *	1987-01-29	1991-05-30	Inhibin Pty Limited	Isolation of single chain proteins with fsh suppressing activity from follicular fluid
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
US5032507A (en) *	1987-11-13	1991-07-16	The Salk Institute For Biological Studies	Potentiation of erythropoiesis

1988
- 1988-11-01 US US07/266,421 patent/US4997815A/en not_active Expired - Fee Related
1989
- 1989-10-31 MA MA21919A patent/MA21667A1/fr unknown
- 1989-10-31 CA CA002001897A patent/CA2001897A1/en not_active Abandoned
- 1989-10-31 IL IL9216789A patent/IL92167A/en not_active IP Right Cessation
- 1989-11-01 EP EP89311297A patent/EP0367590B1/en not_active Expired - Lifetime
- 1989-11-01 JP JP1286002A patent/JPH02256622A/ja active Pending
- 1989-11-01 EP EP94200748A patent/EP0617966A1/en not_active Withdrawn
- 1989-11-01 DE DE68921546T patent/DE68921546T2/de not_active Expired - Fee Related
- 1989-11-01 AT AT89311297T patent/ATE119396T1/de active
- 1989-11-02 PT PT92174A patent/PT92174B/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT92174B (pt)	1995-09-12
CA2001897A1 (en)	1990-05-01
MA21667A1 (fr)	1990-07-01
JPH02256622A (ja)	1990-10-17
EP0367590B1 (en)	1995-03-08
DE68921546T2 (de)	1995-07-06
EP0367590A3 (en)	1992-01-02
ATE119396T1 (de)	1995-03-15
EP0367590A2 (en)	1990-05-09
IL92167A0 (en)	1990-07-12
IL92167A (en)	1994-07-31
US4997815A (en)	1991-03-05
DE68921546D1 (de)	1995-04-13
EP0617966A1 (en)	1994-10-05

Legal Events

Date

Code

Title

Description

1995-09-12

FG3A

Patent granted, date of granting

Effective date: 19950510

1997-03-31

MM3A

Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19961130

Publication	Publication Date	Title
DE68921546D1 (de)	1995-04-13	Erhöhung des fetalen Hämoglobins durch Behandlung mit Aktivin und/oder Inhibin.
CY1112845T1 (el)	2016-02-10	Παραγωγα της 1-δεοξυ-γαλακτονογιριμυκινης και η χρηση τους στη θεραπεια αθροιστικων λυσοσωμικων ασθενειων μεσω ενισχυσης της λυσοσωμικης α-γαλακτοσιδασης α
PT96518A (pt)	1991-10-15	Processo para a preparacao de produtos de adicao de complexos de renio ou de tecnecio-99m e de uma dioxima e de um acido boronico,comportando um grupo bioquimicamente activo, com accao terapeutica ou de diagnostico e de novos compostos intermedios utilizados na sua preparacao
Salmi et al.	1986	Metabolic control in adolescent insulin-dependent diabetics referred from pediatric to adult clinic
FI883936A7 (fi)	1989-02-27	Sokeritaudin hoito, hoidossa käyttökelpoiset valmisteet ja niiden valmistus
IGISU et al.	1975	Giant axonal neuropathy: a clinical entity affecting the central as well as the peripheral nervous system
DK0396184T3 (da)	1996-12-30	Anvendelse af ketoconazol og et retinoid til behandling af acne vulgaris
BR8704328A (pt)	1988-04-19	Compostos,processo para sua preparacao,utilizacao,composicoes fungicidas e processo para combater doencas fungicidas em culturas
Landau	1992	Landau-Kleffner syndrome: an eponymic badge of ignorance
EP0371789A3 (en)	1991-10-02	Medicament for augmenting fetal hemoglobin
Rachman et al.	1987	Is incomplete fear-reduction followed by a return of fear?
ES2022328B3 (es)	1991-12-01	Enchufe de fuerza de insercion cero para fotoactivacion de un sistema de tratamiento de pacientes.
BR8801117A (pt)	1988-10-18	Composto,processo para sua obtencao,composicao para o combate de doencas em plantas,utilizacao e cultura
FI891210A7 (fi)	1989-03-14	Tiosulfiinihappojohdannaiset, niiden käyttö tulehdussairauksien käsitt elyyn sekä näitä aineita sisältävät lääkeaineet
Schor et al.	1983	Rotating grating treatment of amblyopia with and without eccentric fixation
Tollison et al.	1988	Pain clinic# 10. Physical exercise in the treatment of low back pain. Part II: A practical regimen of stretching exercise
RU93003597A (ru)	1995-05-10	Способ лечения свежеперенесенного травматического повреждения головного мозга
王小马 et al.	1988	THE EFFECT OF ACUPUNCTURE IN 90 CASES OF SEQUELAE OF BRAIN CONCUSSION
Bach	1984	Lonazolac-Ca(Irritren), a new non-steroidal antirheumatic agent. Clinical data based on 18, 000 treated patients.
Behrman et al.	1956	Alopecia Areata Due to Syphilis
Yang et al.	1989	A Clinical Study of the Treatment of Ruptures of Deltoid Ligament Associated with Fracture of Distal Part of Fibula
Haber et al.	1984	Assessment of a treatment for epidermolysis bullosa
Palaharn et al.	1998	The evaluation of patient education on epilepsy.
DE69005934D1 (de)	1994-02-24	Bi-aromatische Thioester, Verfahren zu ihrer Herstellung und ihre Verwendung in menschlicher oder tierischer Medizin sowie in Kosmetik.
Malinovskaia et al.	1991	The Holter monitoring of patients with newly occurring and progressing stenocardia